Phase 4
N=30
Spironolactone After Liver Transplant
Transplant, Liver
Bottom Line
View on ClinicalTrials.gov: NCT02883400 ↗Enrolled (actual)
30
Serious AEs
13.3%
Results posted
Jun 2021
Primary outcome: Primary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Spironolactone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Jan 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glomerular Filtration Rate (GFR) |
69; 64 | 0.0001 sig |
Summary
To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.
Eligibility Criteria
Inclusion Criteria
- liver transplant
Exclusion Criteria
- dual organ transplant
Data sourced from ClinicalTrials.gov (NCT02883400). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.